Sharman, J. P., Forero-Torres, A., Costa, L. J., Flinn, I. W., Inhorn, L., Kelly, K., . . . Zelenetz, A. D. (2018). Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: The phase II GATHER study. Leuk Lymphoma.
Citação norma ChicagoSharman, Jeff P., et al. "Obinutuzumab Plus CHOP Is Effective and Has a Tolerable Safety Profile in Previously Untreated, Advanced Diffuse Large B-cell Lymphoma: The Phase II GATHER Study." Leuk Lymphoma 2018.
ציטוט MLASharman, Jeff P., et al. "Obinutuzumab Plus CHOP Is Effective and Has a Tolerable Safety Profile in Previously Untreated, Advanced Diffuse Large B-cell Lymphoma: The Phase II GATHER Study." Leuk Lymphoma 2018.